Therini Bio has initiated a Phase 1b trial of THN391, a monoclonal antibody targeting fibrin's inflammatory epitope, for diabetic macular edema. The approach represents a mechanistic alternative to standard VEGF inhibition, with preclinical data suggesting comparable leakage containment and potential advantages in durability and fibrosis prevention.
Key Points
- THN391 blocks fibrin's inflammatory epitope while preserving coagulation function
- Preclinical data match VEGF antagonists in leakage containment efficacy
- Lead candidate THN622 combines fibrin and VEGF blockade for dual mechanism
Longevity Analysis
Diabetic macular edema accelerates vision loss through a cascade of vascular leakage and neuroinflammatory damage. By targeting fibrin—a structural protein central to both clot formation and inflammatory signaling—this approach addresses the inflammatory driver rather than exclusively blocking growth factors. The preserved coagulation function distinguishes this mechanism from current standards and may reduce systemic bleeding risk. The bispecific strategy reflects growing recognition that single-target interventions often fail to prevent disease progression; combining fibrin and VEGF blockade addresses both the structural breakdown of the retinal barrier and the angiogenic stimulus driving edema. Success would establish a new pathway for retinal degenerative conditions and potentially for other fibrin-mediated neuroinflammatory diseases.
Original published by LT Wire.